Interferon-beta ( @entity2391 ) reduces the number and load of new contrast-enhancing lesions (CELs) in @entity1 with @entity15 ( @entity15 ). However, the ability of @entity2391 to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten @entity1 with relapsing-remitting (RR) @entity15 . These @entity1 underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous @entity2391 -1b, totaling 37 images per @entity1 . The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with @entity2391 therapy. The decrease was greater (P = 0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, @entity2391 -1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, @entity2391 appears to be effective in reducing the degree of severity of @entity32 among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.

Interferon-beta-1b effects on re-enhancing lesions in XXXX with @entity15 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis'] @entity2391 :: ('3456', 'Gene') :: ['IFNbeta']
@entity1 :: (9606,Species) :: ['patients']
